Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a

The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, ran...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Lababidi, Rania M., Mooty, Mohamad, Bonilla, Maria-Fernanda, Salem, Nouran M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242210/
https://www.ncbi.nlm.nih.gov/pubmed/32483527
http://dx.doi.org/10.1016/j.idcr.2020.e00837
_version_ 1783537195456397312
author El-Lababidi, Rania M.
Mooty, Mohamad
Bonilla, Maria-Fernanda
Salem, Nouran M.
author_facet El-Lababidi, Rania M.
Mooty, Mohamad
Bonilla, Maria-Fernanda
Salem, Nouran M.
author_sort El-Lababidi, Rania M.
collection PubMed
description The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19.
format Online
Article
Text
id pubmed-7242210
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72422102020-05-22 Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a El-Lababidi, Rania M. Mooty, Mohamad Bonilla, Maria-Fernanda Salem, Nouran M. IDCases Article The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19. Elsevier 2020-05-22 /pmc/articles/PMC7242210/ /pubmed/32483527 http://dx.doi.org/10.1016/j.idcr.2020.e00837 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
El-Lababidi, Rania M.
Mooty, Mohamad
Bonilla, Maria-Fernanda
Salem, Nouran M.
Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
title Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
title_full Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
title_fullStr Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
title_full_unstemmed Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
title_short Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
title_sort treatment of severe pneumonia due to covid-19 with peginterferon alfa 2a
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242210/
https://www.ncbi.nlm.nih.gov/pubmed/32483527
http://dx.doi.org/10.1016/j.idcr.2020.e00837
work_keys_str_mv AT ellababidiraniam treatmentofseverepneumoniaduetocovid19withpeginterferonalfa2a
AT mootymohamad treatmentofseverepneumoniaduetocovid19withpeginterferonalfa2a
AT bonillamariafernanda treatmentofseverepneumoniaduetocovid19withpeginterferonalfa2a
AT salemnouranm treatmentofseverepneumoniaduetocovid19withpeginterferonalfa2a

Ejemplares similares